RIOX2 and hepatocellular carcinoma: Clinically, because of acquired resistance after sorafenib treatment, which greatly limits its therapeutic efficacy in HCC patients,43, 44 we found and confirmed in this study that the decreased expression of MDIG may be a selective manner to increase the sensitivity of HCC cells to sorafenib, the mechanism of which needs to be further clarified.